

University of Dundee

Genomic correlates of glatiramer acetate adverse cardiovascular effects lead to a novel locus mediating coronary risk

Brænne, Ingrid; Zeng, Lingyao; Willenborg, Christina; Tragante, Vinicius; Kessler, Thorsten; Willer, Cristen J.

Published in:
PLOS ONE

DOI:
[10.1371/journal.pone.0182999](https://doi.org/10.1371/journal.pone.0182999)

Publication date:
2017

Licence:
CC BY

Document Version
Publisher's PDF, also known as Version of record

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):

Brænne, I., Zeng, L., Willenborg, C., Tragante, V., Kessler, T., Willer, C. J., Laakso, M., Wallentin, L., Franks, P. W., Salomaa, V., Dehghan, A., Meitinger, T., Samani, N. J., Asselbergs, F. W., Erdmann, J., Schunkert, H., Deloukas, P., Kanoni, S., Willenborg, C., ... Wellcome Trust Case Control Consortium (2017). Genomic correlates of glatiramer acetate adverse cardiovascular effects lead to a novel locus mediating coronary risk. *PLoS ONE*, 12(8), 1-19. [e0182999]. <https://doi.org/10.1371/journal.pone.0182999>

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.


Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

RESEARCH ARTICLE

Genomic correlates of glatiramer acetate adverse cardiovascular effects lead to a novel locus mediating coronary risk

Ingrid Brænne^{1,2,3}, Lingyao Zeng⁴, Christina Willenborg¹, Vinicius Tragante⁵, Thorsten Kessler⁴, CARDIoGRAM Consortium[¶], CARDIoGRAMplusC4D Consortium[¶], Cristen J. Willer⁶, Markku Laakso⁷, Lars Wallentin⁸, Paul W. Franks⁹, Veikko Salomaa¹⁰, Abbas Dehghan¹¹, Thomas Meitinger^{12,13,14}, Nilesh J. Samani¹⁵, Folkert W. Asselbergs^{5,16,17}, Jeanette Erdmann^{1,2,3*}, Heribert Schunkert^{4,13}



OPEN ACCESS

Citation: Brænne I, Zeng L, Willenborg C, Tragante V, Kessler T, CARDIoGRAM Consortium, et al. (2017) Genomic correlates of glatiramer acetate adverse cardiovascular effects lead to a novel locus mediating coronary risk. PLoS ONE 12(8): e0182999. <https://doi.org/10.1371/journal.pone.0182999>

Editor: Gualtiero I. Colombo, Centro Cardiologico Monzino, ITALY

Received: March 13, 2017

Accepted: July 27, 2017

Published: August 22, 2017

Copyright: © 2017 Brænne et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: This work was supported by grants from the Fondation Leducq (CADgenomics: Understanding CAD Genes, 12CVD02), the German Federal Ministry of Education and Research (BMBF) within the framework of the e:Med research and funding concept (e:AtheroSysMed, grant 01ZX1313A-2014 and SysInflame, grant

1 Institute for Cardiogenetics, University of Lübeck, Lübeck, Germany, **2** DZHK (German Research Center for Cardiovascular Research), partner site Hamburg/Lübeck/Kiel, Lübeck, Germany, **3** University Heart Center Lübeck, Lübeck, Germany, **4** Deutsches Herzzentrum München, Technische Universität München, München, Germany, **5** Department of Cardiology, Division Heart and Lungs, UMC Utrecht, Utrecht, The Netherlands, **6** University of Michigan, Dept of Biostatistics, 1415 Washington Hts, Ann Arbor, MI, United States of America, **7** Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland, **8** Uppsala Clinical Research Center, Uppsala Science Park, MTC, Uppsala, Sweden, **9** Genetic and Molecular Epidemiology Unit, Department of Clinical Sciences, Lund University, Skåne University Hospital Malmö, Malmö, Sweden, **10** THL-National Institute for Health and Welfare, POB 30, Mannerheimintie 166, Helsinki, Finland, **11** Department of Epidemiology, Erasmus University Medical Center, CA Rotterdam, The Netherlands, **12** Institute of Human Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany, **13** DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany, **14** Institute of Human Genetics, Technische Universität München, Munich, Germany, **15** Department of Cardiovascular Sciences University of Leicester and NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester, United Kingdom, **16** Durrer Center for Cardiovascular Research, Netherlands Heart Institute, Utrecht, the Netherlands, **17** Institute of Cardiovascular Science, faculty of Population Health Sciences, University College London, London, United Kingdom

¶ The memberships of CARDIoGRAM and CARDIoGRAMplusC4D consortia are provided in the Acknowledgments.

* jeanette.erdmann@uni-luebeck.de

Abstract

Glatiramer acetate is used therapeutically in multiple sclerosis but also known for adverse effects including elevated coronary artery disease (CAD) risk. The mechanisms underlying the cardiovascular side effects of the medication are unclear. Here, we made use of the chromosomal variation in the genes that are known to be affected by glatiramer treatment. Focusing on genes and gene products reported by drug-gene interaction database to interact with glatiramer acetate we explored a large meta-analysis on CAD genome-wide association studies aiming firstly, to investigate whether variants in these genes also affect cardiovascular risk and secondly, to identify new CAD risk genes. We traced association signals in a 200-kb region around genomic positions of genes interacting with glatiramer in up to 60 801 CAD cases and 123 504 controls. We validated the identified association in additional 21 934 CAD cases and 76 087 controls. We identified three new CAD risk alleles within the TGFB1 region on chromosome 19 that independently affect CAD risk. The lead SNP rs12459996 was genome-wide significantly associated with CAD in the extended

01ZX1306A), and the European Union Seventh Framework Programme FP7/2007-2013 under grant agreement no HEALTH-F2-2013-601456 (CVgenes-at-target). Further grants were received from the DFG as part of the Sonderforschungsbereich CRC 1123 (B2). T.K. was supported by a DZHK Rotation Grant. I.B. was supported by the Deutsche Forschungsgemeinschaft (DFG) cluster of excellence 'Inflammation at Interfaces'. F.W.A. is supported by a Dekker scholarship-Junior Staff Member 2014T001 – Netherlands Heart Foundation and UCL Hospitals NIHR Biomedical Research Centre. This work was supported by the German Research Foundation (DFG) and the Technical University of Munich within the funding programme Open Access Publishing.

Competing interests: P.W.F. reports grants from Sanofi Aventis, grants from Lilly, grants from Novo nordisk, personal fees from Sanofi Aventis, personal fees from Lilly. L.W. reports institutional research grants, consultancy fees, lecture fees, and travel support from AstraZeneca, institutional research grants, consultancy fees, lecture fees, and travel support from Boehringer Ingelheim, institutional research grants, consultancy fees, lecture fees, and travel support from Bristol-Myers Squibb/Pfizer, grants from Merck & Co, grants from Roche, consultancy fees from Abbott and holds two patents involving GDF-15. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

meta-analysis (odds ratio 1.09, $p = 1.58 \times 10^{-12}$). The other two SNPs at the locus were not in linkage disequilibrium with the lead SNP and by a conditional analysis showed p-values of 4.05×10^{-10} and 2.21×10^{-6} . Thus, studying genes reported to interact with glatiramer acetate we identified genetic variants that concordantly with the drug increase the risk of CAD. Of these, TGFB1 displayed signal for association. Indeed, the gene has been associated with CAD previously in both in vivo and in vitro studies. Here we establish genome-wide significant association with CAD in large human samples.

Introduction

Glatiramer acetate (GA), also known under the trade name Copaxone®, is an immunomodulator used in the treatment of relapsing-remitting multiple sclerosis (MS). It is a synthetic peptide consisting of four amino acids[1, 2]. GA is assumed to bind major histocompatibility complex (MHC) molecules and compete with various myelin antigens[2]. This competitive binding affects the presentation of myelin antigens to T-cells. In addition, GA potentially promotes suppressor T-cells[1, 3]. A further mechanism of action is that GA-induced T helper cells secrete high amounts of cytokines such as IL-4/10 and TGF-β[2]. In mice, GA is reported to induce transforming growth factor β 1 (TGFB1) in several cell types such as monocytes[4], Th2/3 cells[5] and brain[6]. In addition, it is known that polymorphisms in the TGFB1 gene alter the GA treatment response[7].

According to the FDA, drugs.com and the copaxone own webpage (copaxone.com), GA is reported to induce hypertension and increase the risk of coronary artery disease (CAD) and myocardial infarction. The exact mechanisms that explain the increased risk of CAD or hypertension under GA treatment are, however, not fully understood.

Understanding the genetic mechanisms underlying a disease can facilitate the identification of new drug targets. Indeed, several drugs have been developed based on genetic findings [8–10]. Moreover, if we know which genes or pathways are targeted by a drug, we may also predict adverse effects based on variants in these genes modulating risk[11, 12]. Here, we reversed this approach to identify new disease risk genes. We screened genes that are reported to interact with a drug that increases the risk of CAD to identify new CAD risk alleles. In a previous study, we identified new CAD risk genes by studying the pleiotropic effects of cyclooxygenase 2 inhibitors[13].

In this work, we first identified genes and gene products reported to interact with GA. These genes were then screened for association in the largest meta-analysis on CAD genome-wide association studies (GWAS), CARDIoGRAMplusC4D 1000G[14]. The underlying idea is that single nucleotide polymorphisms (SNPs) in *cis* with these genes may affect expression or structure of these genes in a similar way as the drug. Hence, we expect that some of these SNPs also may increase the risk of CAD, even though the effect size might vary between drug and variant.

Methods

The first step of the analysis was to identify genes or gene products reported to interact with GA. For this, we used the Drug Gene Interaction Database (DGIdb)[15]. Second, in a large CAD GWAS dataset, we identified all SNPs within 200kb surrounding the four genes identified in the first step of this analysis. The 200kb window was selected to also include regulatory SNPs affecting gene expression.

GWAS dataset

The CARDIoGRAMplusC4D 1000Genomes meta-analysis data set consists of 47 GWAS studies including 60 801 CAD cases and 123 504 controls. Ethical approval was obtained from the appropriate ethics committees and informed consent was obtained from all participants. Specifically, the studies involving genome-wide SNP analysis for CAD were approved by the ethics commissions of the University of Regensburg (02/042), the University of Lübeck (04/041) and the Technical University of Munich (406/15s). The GWAS are imputed with the December 2012 1000Genomes phase I integrated haplotypes (<ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20110521/>) (for Methods see Nikpay et al. [14]).

We validated and later combined the CARDIoGRAMplusC4D 1000Genomes meta-analysis data set [14] with GWAS data from CHARGE, deCODE CAD, DILGOM, EPIC, FRISC II, GLACIER, METISM, MORGAM FIN, MORGAM FRA, MORGAM GER, MORGAM ITA, MORGAM UNK, PMB, PopGen, SCARF SHEEP, and STR that have been previously reported in references Schunkert et al. [16] and/or Deloukas et al. [17]. Moreover, we included data from GWAS not reported before, i.e. German MI Family Studies V. See detailed information in S1 Table. In total, this combined dataset consists of 82 735 cases and 199 591 controls. Compared to the CARDIoGRAMplusC4D study, we increase the sample size by 21.934 cases and 76.087 controls.

Meta-analysis

Logistic regression, assuming an additive model, was performed on all single study data. All analyses were adjusted for sex and age. Age was defined as the recruitment age for controls and the event age for cases. We used the fixed-effect inverse variance-weighted meta-analysis to combine single analyses data. Quality control was performed at individual sites and centrally to assure standardized data formats previously agreed criteria including check of consistency of the given alleles across all studies, quality of the imputation, deviation from Hardy-Weinberg equilibrium and call rate. If individuals or single studies did not pass quality control, they were excluded. SNPs were also excluded from the meta-analysis if present in less than 17 GWAS.

For the meta-analysis, we calculated an 'inverse variance weighting' - fixed-effects and a random effects model [18], depending on the heterogeneity between the studies. For heterogeneity calculation, Cochran's Q was used. The threshold for heterogeneity was $p_{het} < 0.01$. For the combination of the stages (stage 1: results of 1000G meta-analysis; stage 2: replication in CARDIoGRAM, CARDIoGRAMplusC4D, GerMIPS V) an 'inverse variance weighting' - the fixed-effects model was calculated and the combined effects and p-values were reported. In total, we evaluated the genomic data from 82 735 cases and 199 591 controls.

Statistical methods

The number of SNPs tested in the initial screen (for the four genes) is 20,027. We corrected the p-value threshold based on the number of SNPs tested using the Bonferroni correction. Hence, all SNPs with p-values below 2.5×10^{-6} were considered significant.

Identification of TGFB1 sub-loci

We used Haploreg version 4.1 [19] with the European 1000G Phase 1 database for LD calculation. We identified LD blocks based on $LD > 0.4$ to the lead SNPs. In detail, we repeated the following three steps until no sub-loci with a p-value below 1×10^{-6} were found.

1. Identification of current lead SNP (SNP with the lowest p-value).

2. Identify all SNPs in LD ($r^2 > 0.4$) with the current lead SNP.
3. Remove lead and LD SNPs from dataset

To test for independence between the identified sub-loci, we performed conditional analysis using summary statistic data with the GCTA tool[20]. As reference data used the GerMIFs II study. For conditional analysis, we used the SNPs identified in the above-described sub-loci analysis. We first performed a joint analysis using the—cojo-joint option and then performed the conditional analysis (—cojo-cond) based on the independent SNPs identified in the joint analysis step.

Functional annotation of SNPs and TGFB1

To evaluate the functional implication of the SNPs, we identified all SNPs in high LD ($r^2 > 0.8$) with the locus lead SNP using the HaploReg version 4.1 database[19]. To estimate the effect of a SNP on gene expression, we identified expression quantitative trait loci (eQTLs) using the publicly available data from Westra et al.[21], GTEx[22] as well as over 100 studies included in the Genome-Wide Repository of Associations between SNPs and Phenotypes (GRASP) database[23]. In addition, we used HaploReg and RegulomeDB[24] to functionally annotate SNPs and performed a literature search for gene functions using Pubmed.

Results

The principle idea of this approach is illustrated in Fig 1. Using DGIdb[15], we identified four genes reported to interact with GA; CCR5, HLA-DRB1, IFNAR1, and TGFB1. Of these, only the TGFB1 region displayed signals suggesting an association with CAD risk (Fig 2). We




Fig 1. Schematic approach. 1) Identification of reported adverse effect of GA 2) Identify genes reported to interact with GA. 3) Establish a link between the genes identified in 2. and the adverse effect identified in 1).

<https://doi.org/10.1371/journal.pone.0182999.g001>




Fig 2. GA interacts with CCR, TGFB1, IFNAR1 and HLA-DRB1 (solid line). Moreover, it is known that GA affects CAD (Coronary Artery Disease) risk (dashed line). In this work, we searched for SNPs associated with CAD in the gene regions representing the GA off target effects (dotted lines). We found a genome-wide significant association for the TGFB1 locus with a p-value of 1.58×10^{-12} (red dotted line). n.s.: non-significant; TGFB1: Transforming Growth Factor, Beta 1; CCR5: Chemokine (C-C Motif) Receptor 5 (Gene/Pseudogene); IFNAR1: Interferon (Alpha, Beta And Omega) Receptor 1; HLA-DRB1: Major Histocompatibility Complex, Class II, DR Beta 1.

<https://doi.org/10.1371/journal.pone.0182999.g002>

validated the GA-TGFB1 interaction performing a literature search[2, 4–6]. Moreover, from a mechanistic point of view, TGFB1 is the only gene with evidence of a functional association with CAD (see S1 Fig). Hence, we did not examine the other genes further.

In our first GWAS look-up, the lead SNP, rs15052, close to TGFB1 yielded a p-value of 2.21×10^{-7} . In a replication study with independent samples, rs15052 showed a p-value of 9.97×10^{-4} , hence validating the initial finding. We next combined the data sets and reran the analysis. In this combined meta-analysis, rs15052 yielded a genome-wide significant p-value of 9.11×10^{-10} . The new lead SNP in the joint meta-analysis, rs12459996 had a p-value of 1.58×10^{-12} and an OR of 1.09 (see Fig 3).

The TGFB1 locus presumably harbors several independent sub-loci (see Table 1). Using the GCTA conditional analysis on summary statistic data, we identified three such independent signals. In addition to the genome-wide significant lead SNP, two sub-loci show significant p-values (rs1056854: 3.30×10^{-7} and rs75041078: 3.87×10^{-7}). We conditioned the two new SNPs on rs12459996 in a stepwise approach. rs1056854 showed the lowest p-value after conditioning with rs12459996 with a p-value of 4.07×10^{-10} and an OR of 1.07. Conditioning rs75041078 on the lead SNPs rs12459996 and rs1056854, we get a p-value for the third SNP of 2.21×10^{-6} with an OR of 1.05.




Fig 3. Association sub-loci signal for the TGFB1 locus. The three lead SNPs are shown with the corresponding high-LD blocks (SNPs within $r^2 > 0.2$.) depicted in orange, red and green. Independent sub-loci were identified with the GCTA conditional analysis tool (see [methods](#)). The LD between the lead SNPs indicated and under $r^2 < 0.1$. The three individual LocusZoom plots are found in the [S2 Fig](#).

<https://doi.org/10.1371/journal.pone.0182999.g003>

Table 1. TGFB1 locus.

Sub-locus	Lead SNP	CAD risk allele	Frequency risk allele	OR (CI) risk allele	P-value combined analysis	P-value joint analysis GCTA	OR risk allele joint analysis GCTA	SNP effect on TGFB1	Regulatory function Haploreg	Regulatory function Regulome score
I	rs12459996	T	0.10	1.09 (1.06–1.12)	1.58×10^{-12}	2.73×10^{-9}	1.09	Increased expression	enhancer	6
II	rs75041078	A	0.25	1.06 (1.04–1.09)	3.87×10^{-7}	4.05×10^{-10}	1.07	n/a	enhancer	n/a
III	rs1056854	A	0.86	1.06 (1.04–1.08)	3.30×10^{-7}	2.21×10^{-6}	1.05	increased expression	enhancer	5

<https://doi.org/10.1371/journal.pone.0182999.t001>

To evaluate the functional implication of the three potentially independent associations, we performed an in-silico evaluation of the lead SNPs and the SNPs in high LD with these ($r^2 > 0.8$) (see [S2 Table](#) for detailed results).

The genome-wide significant lead SNP rs12459996 ($p = 1.58 \times 10^{-12}$; OR = 1.09), is found in a regulatory region and is marked as a strong promoter and enhancer in several cell types including smooth muscle and T-helper cells. As the promoter marks are downstream TGFB1, it is more likely that the regulatory effect on TGFB1 is acting through the enhancer. The lead SNP and SNPs in high LD ($r^2 > 0.8$) are reported to have an eQTL effect on TGFB1 in the thyroid gland ($p = 3.0 \times 10^{-8}$, OR = 1.58) and the skeletal muscle ($p = 5.6 \times 10^{-6}$, 1.36) (GTEx). The CAD risk allele T is associated with increased TGFB1 expression in both cell types.

The second sub-locus has the lead SNP rs75041078 (conditional $p = 4.07 \times 10^{-10}$, conditional OR = 1.07). This SNP is not in high LD with any other SNP ($r^2 > 0.8$). It is located in the intron of TMEM91 and lies in an enhancer histone mark in neutrophils. We did not find any eQTL effect in the databases searched.

The third sub-locus, with the lead SNP rs1056854 (conditional $p = 2.21 \times 10^{-6}$, conditional OR = 1.05), is also located in a regulatory region, which includes a promoter histone mark in various cell types, including H1-hESC cells. The locus is, however, downstream or rather at the 3' end of the TGFB1 gene and hence the promoter unlikely to affect the TGFB1 gene. SNPs in high LD are also found in enhancer histone marks in multiple cell types, including T cells, T-helper cells and monocytes. Hence, the locus might have a regulatory effect on TGFB1. Supporting this hypothesis, we identified an eQTL effect on TGFB1 in the adrenal gland, suggesting a link between the SNP and the gene also in other tissues. The CAD risk allele A is associated with increased expression of TGFB1 ($p = 1.5 \times 10^{-6}$, OR = 2.2).

Discussion

Exploring drug-gene interactions, we identified four genes or gene products to be affected by glatiramer acetate, a drug known to increase the risk of severe coronary events. Analyzing the genomic loci harboring these genes, we identified TGFB1 as a new genome-wide significant locus displaying association for CAD. The results of this analysis give rise to the hypothesis that the known interaction of GA with TGFB1 may be responsible for modulating the risk of CAD. Indeed, the results point towards a novel mechanism for the increased risk of CAD under GA treatment.

The pharmacologic mechanisms of GA in the treatment of multiple sclerosis are not fully understood. The general assumption is that the immune-modulatory activity of GA is related to the change of the T-cell antigen reactivity. Through its presumed binding to the MHC class II, GA is thought to alter the presentation of myelin antigens to auto-reactive T-cells and thereby affects the activity of the antigen presenting cells[25]. It is also known that GA induces the secretion of cytokines such as IL-4/10 and TGF- β in T-helper cells[2], which according to the present data may affect the risk of CAD under GA treatment.

TGFB1 (transforming growth factor, beta1) is a multifunctional peptide controlling multiple cellular functions such as proliferation and differentiation in several cell types. It plays an important role in the pathophysiology of the endothelial and vascular smooth muscle cell. TGFB1 is a very likely CAD candidate gene and has been linked to a range of cardiovascular traits such as atherosclerosis, hypertension, inflammation and aneurysm [26–29]. TGFB1 serum levels are also reported to be higher in CAD patients[30]. In addition, several variants within other genes in the TGFB–SMAD signaling pathway have been associated with CAD[26, 29, 31–34]. It is, hence, also possible, that GAs interaction with TGFB1 influences other reported adverse effects such as the increased risk of hypertension. We cannot exclude that the GA

related risk of CAD is secondary to GA induced hypertension, but at the same time we can also not exclude other pathways. TGFB1 is involved in multiple cellular functions suggesting increased CAD risk through multiple pathways.

Here, we identified three independent CAD associated signals within the TGFB1 locus. The TGFB1 locus has not been genome-wide significantly associated with CAD before, most likely due to small effect sizes and hence insufficient power of previous studies. The three variants are not associated with CAD related traits based on a GRASP database search ($p < 1 \times 10^{-4}$). However, the overlap of the locus with immune cell histone marks suggest a link to inflammation. The lead SNP (rs12459996) of the TGFB1 locus is reported to increase the expression of the gene, which matches with the direction of effect reported for GA. In addition, the risk allele of the sub-locus rs1056854 is also associated with increased expression of the gene. The identified TGFB1 locus is also associated with expression of other genes (CCDC97, HNRNPUL1, AXL, BCKDHA) (see [S2 Table](#)). Because our study focused on genes that interact with GA, we did not discuss these genes at this locus. It is however possible, that these genes influence the risk of CAD as well. Indeed, several studies have demonstrated that a regulatory SNPs have effects on more than one gene. In a previous study, we found multiple genes per locus where either all SNPs, a subset or only one SNP increase the risk of CAD[35].

The molecular effects of TGFB have been extensively studied *in vitro* and *in vivo* models linking the gene to CAD risk. For example, TGFB1 has been associated with several CAD related phenotypes such as thrombosis, inflammation, hypertension and neointima growth [36–44]. However, the net effect of TGFB may vary. Indeed, TGFB1 may either increase or decrease inflammation, activate or deactivate macrophages, depending on the local cytokine environment[29]. This is mainly due to the fact that it acts through several signaling pathways affecting several CAD related phenotypes with partially opposing effect on risk [29, 33]. In early stages of the disease, TGFB1 may be atheroprotective and higher levels of TGFB1 have been reported to decrease the risk of atherosclerosis[29]. In fact, TGFB1 displayed dosage effects where lower levels of TGFB1 increased proliferation whereas higher levels inhibited proliferation in endothelial cells[36]. Vice versa, in the presence of disease increased TGFB1 signaling has been associated with increased restenosis by increasing neointima growth[37, 38]. Moreover, TGFB1 has been linked to accelerated thrombus formation by inducing platelet aggregation [39, 40] and the expression is increased in rats with traumatic deep vein thrombosis versus control rats [41]. TGFB1 was also found to inhibit nitric oxide in vascular endothelial cells linking higher levels of TGFB1 to increased blood pressure[42, 43]. In addition, TGFB1 expression was also reported to be increased in patients with hypertension[44].

Our study design has several limitations. Our findings are based on associations rather than on functional testing. We thus cannot infer the precise pathway that is affected by the genetic variants at the TGFB1 locus. However, functional effects of the risk allele on expression levels have been previously reported and go in the same direction of TGFB1 expression as the effects reported in the literature for GA. Moreover, the association between the TGFB1 locus and CAD risk reaches genome-wide significance, which can be regarded as a conclusive and scientifically important observation independently of the overlap with GA side effects including enhanced TGFB1 expression. Indeed, the links reported here, first between GA and CAD risk ([drugs.com](#)), second between GA and TGFB1[2] and third the genome-wide significant association of TGFB1 SNPs with CAD are each highly conclusive. Together they allow hypothesizing that TGFB1 is involved in the increased risk of CAD under GA treatment.

Taken together, our results imply mechanistic similarities between pharmacologic responses to GA treatment and genetic variants affecting CAD risk. While GA treatment is known to enhance TGFB1 expression and CAD risk, we here associate SNPs within the TGFB1 locus linked with CAD risk and enhanced TGFB1 expression. Thus, both the newly

identified CAD risk alleles and GA appear to induce the expression of TGFB1, suggesting that the CAD risk alleles and the drug have similar effects on the gene product and subsequently on CAD risk. With an additive effect, the CAD risk alleles might also explain variable CAD risk under GA treatment. Finally, in this study, we identified TGFB1 as a new genome-wide significant locus affecting CAD risk.

Supporting information

S1 Fig. CAD association results. Association sub-loci signal for the genes reported to interact with glatiramer acetate. A) TGFB1: Transforming Growth Factor, Beta 1; B) IFNARI: Interferon (Alpha, Beta And Omega) Receptor 1; C) CCR5: Chemokine (C-C Motif) Receptor 5 (Gene/Pseudogene); D) HLA-DRB1: Major Histocompatibility Complex, Class II, DR Beta 1. (TIFF)

S2 Fig. Association sub-loci signal for the TGFB1 locus. Independent sub-loci signal for the TGFB1 locus. A) rs12459996, B) rs1056854, C) rs75041078. (TIFF)

S1 Table. Additional samples for meta-analysis. Additional 21,934 CAD cases and 76,087 controls used for validation and extended meta-analysis. The sample size differs between SNPs for replication as not all SNPs are found in all studies. (DOCX)

S2 Table. Haploreg V4.1 annotation. Functional implication of the SNPs annotated with HaploReg version 4.1 database. (XLSX)

Acknowledgments

This work was supported by grants from the Fondation Leducq (*CADgenomics*: Understanding CAD Genes, 12CVD02), the German Federal Ministry of Education and Research (BMBF) within the framework of the e:Med research and funding concept (*e:AtheroSysMed*, grant 01ZX1313A-2014 and *SysInflame*, grant 01ZX1306A), and the European Union Seventh Framework Programme FP7/2007-2013 under grant agreement n° HEALTH-F2-2013-601456 (*CVgenes-at-target*). Further grants were received from the DFG as part of the Sonderforschungsbereich CRC 1123 (B2). T.K. was supported by a DZHK Rotation Grant. I.B. was supported by the Deutsche Forschungsgemeinschaft (DFG) cluster of excellence 'Inflammation at Interfaces'. F.W.A. is supported by a Dekker scholarship-Junior Staff Member 2014T001 - Netherlands Heart Foundation and UCL Hospitals NIHR Biomedical Research Centre.

CARDIoGRAMplusC4D members

Panos Deloukas¹, Stavroula Kanoni¹, Christina Willenborg², Martin Farrall^{3,4}, Themistocles L Assimes⁵, John R Thompson⁶, Erik Ingelsson⁷, Danish Saleheen^{8–10}, Jeanette Erdmann², Benjamin A Goldstein⁵, Kathleen Stirrups¹, Inke R König¹¹, Jean-Baptiste Cazier⁴, Åsa Johansson¹², Alistair S Hall¹³, Jong-Young Lee¹⁴, Cristen J Willer^{15,16}, John C Chambers¹⁷, Tõnu Esko^{18,19}, Lasse Folkersen^{20,21}, Anuj Goel^{3,4}, Elin Grundberg²², Aki SHavulinna²³, Weang K Ho¹⁰, Jemma C Hopewell^{24,25}, Niclas Eriksson¹², Marcus E Kleber^{26,27}, Kati Kristiansson²³, Per Lundmark²⁸, Leo-Pekka Lyytikäinen^{29,30}, Suzanne Rafelt³¹, Dmitry Shungin^{32–34}, Rona J Strawbridge^{20,21}, Gudmar Thorleifsson³⁵, Emmi Tikkanen^{36,37}, Natalie Van Zuydam³⁸, Benjamin F Voight³⁹, Lindsay L Waite⁴⁰, Weihua Zhang¹⁷, Andreas Ziegler¹¹, Devin Absher⁴⁰, David Altshuler^{41–44}, Anthony J Balmforth⁴⁵, Inês Barroso^{1,46}, Peter

SBraund^{31,47}, Christof Burgdorf⁴⁸, Simone Claudi-Boehm⁴⁹, David Cox⁵⁰, Maria Dimitriou⁵¹, Ron Do^{41,43}, Alex SF Doney³⁸, Nour Eddine El Mokhtari⁵³, Per Eriksson^{20,21}, Krista Fischer¹⁸, Pierre Fontanillas⁴¹, Anders Franco-Cereceda⁵⁴, Bruna Gigante⁵⁵, Leif Groop⁵⁶, Stefan Gustafsson⁷, Jörg Hager⁵⁷, Göran Hallmans⁵⁸, Bok-Ghee Han¹⁴, Sarah EHunt¹, Hyun M Kang⁵⁹, Thomas Illig⁶⁰, Thorsten Kessler⁴⁸, Joshua W Knowles⁵, Genovefa Kolovou⁶¹, Johanna Kuusisto⁶², Claudia Langenberg⁶³, Cordelia Langford¹, Karin Leander⁵⁵, Marja-Liisa Lokki⁶⁴, Anders Lundmark²⁸, Mark I McCarthy^{3,65,66}, Christa Meisinger⁶⁷, Olle Melander⁵⁶, Evelin Mihailov¹⁹, Seraya Maouche⁶⁸, Andrew D Morris³⁸, Martina Müller-Nurasyid^{69–72}, MuTHER Consortium, Kjell Nikus⁷³, John F Peden³, N. William Rayner³, Asif Rasheed⁹, Silke Rosinger⁷⁴, Diana Rubin⁵³, Moritz P Rumpf⁴⁸, Arne Schäfer⁷⁵, Mohan Sivananthan^{76,77}, Ci Song⁷, Alexandre F R Stewart^{78,79}, Sian-Tsung Tan⁸⁰, Gudmundur Thorgeirsson^{81,82}, C Ellen van der Schoot⁸³, Peter J Wagner^{36,37}, Wellcome Trust Case Control Consortium, George A Wells^{78,79}, Philipp S Wild^{84,85}, Tsun-Po Yang¹, Philippe Amouyel⁸⁶, Dominique Arveiler⁸⁷, Hanneke Basart⁸⁸, Michael Boehnke⁵⁹, Eric Boerwinkle⁸⁹, Paolo Brambilla⁹⁰, Francois Cambien⁶⁸, Adrienne L. Cupples^{91,92}, Ulf de Faire⁵⁵, Abbas Dehghan⁹³, Patrick Diemert⁹⁴, Stephen E Epstein⁹⁵, Alun Evans⁹⁶, Marco M Ferrario⁹⁷, Jean Ferrières⁹⁸, Dominique Gauguier^{3,99}, Alan S Go¹⁰⁰, Alison H Goodall^{31,47}, Villi Gudnason^{81,101}, Stanley L Hazen¹⁰², Hilma Holm³⁵, Carlos Iribarren¹⁰⁰, Yangsoo Jang¹⁰³, Mika Kähönen¹⁰⁴, Frank Kee¹⁰⁵, Hyo-Soo Kim¹⁰⁶, Norman Klopp⁶⁰, Wolfgang Koenig¹⁰⁷, Wolfgang Kratzer¹⁰⁸, Kari Kuulasmaa²³, Markku Laakso⁶², Reijo Laaksonen¹⁰⁸, Ji-Young Lee¹⁴, Lars Lind²⁸, Willem H Ouwehand^{1,109,110}, Sarah Parish^{24,25}, Jeong E Park¹¹¹, Nancy L Pedersen⁷, Annette Peters^{67,112}, Thomas Quertermous⁵, Daniel J Rader¹¹³, Veikko Salomaa²³, Eric Schadt¹¹⁴, Svati H Shah^{115,116}, Juha Sinisalo¹¹⁷, Klaus Stark¹¹⁸, Kari Stefansson^{35,81}, David-Alexandre Trégouët⁶⁸, Jarmo Virtamo²³, Lars Wallentin¹², Nicholas Wareham⁶³, Martina E Zimmermann¹¹⁸, Markku S Nieminen¹¹⁷, Christian Hengstenberg¹¹⁸, Manjinder S Sandhu^{1,63}, Tomi Pastinen¹¹⁹, Ann-Christine Syvänen²⁸, G Kees Hovingh⁸⁸, George Dedoussis⁵¹, Paul W Franks^{32–34,120}, Terho Lehtimäki^{29,30}, Andres Metspalu^{18,19}, Pierre A Zalloua¹²¹, Agneta Siegbahn¹², Stefan Schreiber⁷⁵, Samuli Ripatti^{1,37}, Stefan S Blankenberg⁹⁴, Markus Perola²³, Robert Clarke^{24,25}, Bernhard OBoehm⁷⁴, Christopher O'Donnell⁹³, Muredach P Reilly^{122,126}, Winfried März^{26,123}, Rory Collins^{24,25,126}, Sekar Kathiresan^{41,124,125,126}, Anders Hamsten^{20,21,126}, Jaspal S Kooner^{80,126}, Unnur Thorsteinsdottir^{35,81,126}, John Danesh^{9,126}, Colin NA Palmer^{38,126}, Robert Roberts^{78,79,126}, Hugh Watkins^{3,4,126}, Heribert Schunkert^{48,126} & Nilesh J Samani^{31,47,126}

Affiliations CARDIoGRAM plus C4D

1Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK. 2Institut für Integrative und Experimentelle Genomik, Universität zu Lübeck, Lübeck, Germany. 3Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK. 4Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK. 5Department of Medicine, Stanford University School of Medicine, Stanford, California, USA. 6Department of Health Sciences, University of Leicester, Leicester, UK. 7Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. 8Center for Non-Communicable Diseases, Karachi, Pakistan. 9Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. 10Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 11Institut für Medizinische Biometrie und Statistik, Universität zu Lübeck, Lübeck, Germany. 12Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden. 13Division of Cardiovascular and Neuronal Remodelling, Multidisciplinary Cardiovascular Research Centre, Leeds Institute of Genetics, Health and Therapeutics, University of

Leeds, Leeds, UK. 14Center for Genome Science, Korea National Institute of Health, Korea. 15Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA. 16Department of Human Genetics, University of Michigan, Ann Arbor, Michigan, USA. 17Department of Epidemiology and Biostatistics, Imperial College London, London, UK. 18Estonian Genome Center, University of Tartu, Tartu, Estonia. 19Institute of Molecular and Cell Biology, University of Tartu, Tartu, Estonia. 20Atherosclerosis Research Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden. 21Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden. 22Department of Twin Research and Genetic Epidemiology, King's College London, London, UK. 23Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland. 24Clinical Trial Service Unit, University of Oxford, Oxford, UK. 25Epidemiological Studies Unit, University of Oxford, Oxford, UK. 26Mannheim Institute of Public Health, Social and Preventive Medicine, Medical Faculty of Mannheim, University of Heidelberg, Mannheim, Germany. 27Ludwigshafen Risk and Cardiovascular Health (LURIC) Study, Freiburg, Germany. 28Department of Medical Sciences, Uppsala University, Uppsala, Sweden. 29Department of Clinical Chemistry, Fimlab Laboratories, Tampere University Hospital, Tampere, Finland. 30Department of Clinical Chemistry, University of Tampere School of Medicine, Tampere, Finland. 31Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Leicester, UK. 32Genetic & Molecular Epidemiology Unit, Department of Clinical Sciences, Lund University Diabetes Center, Skåne University Hospital, Malmö, Sweden. 33Department of Public Health & Clinical Medicine, Genetic Epidemiology & Clinical Research Group, Section for Medicine, Umeå University, Umeå, Sweden. 34Department of Odontology, Umeå University, Umeå, Sweden. 35deCODE Genetics, Reykjavik, Iceland. 36Institute for Molecular Medicine FIMM, University of Helsinki, Helsinki, Finland. 37Public Health Genomics Unit, National Institute for Health and Welfare, Helsinki, Finland. 38Medical Research Institute, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK. 39Department of Pharmacology, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 40HudsonAlpha Institute for Biotechnology, Huntsville, Alabama, USA. 41Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA. 42Department of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts, USA. 43Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts, USA. 44Department of Genetics, Harvard Medical School, Boston, Massachusetts, USA. 45Division of Cardiovascular and Diabetes Research, Multidisciplinary Cardiovascular Research Centre, Leeds Institute of Genetics, Health and Therapeutics, University of Leeds, Leeds, UK. 46University of Cambridge Metabolic Research Laboratories, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK. 47National Institute for Health Research (NIHR) Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester, UK. 48Deutsches Herzzentrum München, Technische Universität München, Munich, Germany. 49Practice of Gynecology, Ulm University Medical Centre, Ulm, Germany. 50Biotherapeutics and Bioinnovation Center, Pfizer, South San Francisco, California, USA. 51Department of Dietetics–Nutrition, Harokopio University, Athens, Greece. 52Klinik für Innere Medizin, Kreiskrankenhaus Rendsburg, Rendsburg, Germany. 53Cardiothoracic Surgery Unit, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. 54Division of Cardiovascular Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. 55Department of Clinical Sciences, Diabetes and Endocrinology, Lund University, University Hospital Malmö, Malmö, Sweden. 56Commissariat à l'Energie Atomique (CEA)–Genomics Institute, National Genotyping Centre, Paris, France. 57Department of Public Health & Clinical Medicine, Section for Nutritional Research, Umeå University, Umeå,

Sweden. 59Department of Biostatistics, Center for Statistical Genetics, University of Michigan, Ann Arbor, Michigan, USA. 60Hannover Unified Biobank, Hannover Medical School, Hannover, Germany. 61First Cardiology Department, Onassis Cardiac Surgery Center 356, Athens, Greece. 62Department of Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland. 63Medical Research Council (MRC) Epidemiology Unit, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK. 64Transplantation Laboratory, Haartman Institute, University of Helsinki, Helsinki, Finland. 65Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK. 66Oxford NIHR Biomedical Research Centre, Churchill Hospital, Oxford, UK. 67Institute of Epidemiology II, Helmholtz Zentrum München—German Research Center for Environmental Health, Neuherberg, Germany. 68Institut National de la Santé et la Recherche Médicale (INSERM) Unité Mixte de Recherche (UMR) S937, Institute for Cardiometabolism and Nutrition (ICAN), Pierre and Marie Curie (Paris 6) University, Paris, France. 69Department of Medicine I, University Hospital Grosshadern, Ludwig-Maximilians-Universität, Munich, Germany. 70Chair of Epidemiology, Institute of Medical Informatics, Biometry and Epidemiology, Ludwig-Maximilians-Universität, Munich, Germany. 71Chair of Genetic Epidemiology, Institute of Medical Informatics, Biometry and Epidemiology, Ludwig-Maximilians-Universität, Munich, Germany. 72Institute of Genetic Epidemiology, Helmholtz Zentrum München—German Research Center for Environmental Health, Neuherberg, Germany. 73Heart Centre, Department of Cardiology, Tampere University Hospital, Tampere, Finland. 74Division of Endocrinology and Diabetes, Department of Internal Medicine, Ulm University Medical Centre, Ulm, Germany. 75Institut für Klinische Molekularbiologie, Christian-Albrechts Universität, Kiel, Germany. 76Division of Epidemiology, Multidisciplinary Cardiovascular Research Centre (MCRC) University of Leeds, Leeds, UK. 77Leeds Institute of Genetics, Health and Therapeutics, University of Leeds, Leeds, UK. 78University of Ottawa Heart Institute, Cardiovascular Research Methods Centre Ontario, Ottawa, Ontario, Canada. 79Ruddy Canadian Cardiovascular Genetics Centre, Ottawa, Ontario, Canada. 80National Heart and Lung Institute (NHLI), Imperial College London, Hammersmith Hospital, London, UK. 81Faculty of Medicine, University of Iceland, Reykjavik, Iceland. 82Department of Medicine, Landspítali University Hospital, Reykjavik, Iceland. 83Department of Experimental Immunohematology, Sanquin, Amsterdam, The Netherlands. 84Center for Thrombosis and Hemostasis, University Medical Center Mainz, Johannes Gutenberg University Mainz, Mainz, Germany. 85Department of Medicine 2, University Medical Center Mainz, Johannes Gutenberg University Mainz, Mainz, Germany. 86Institut Pasteur de Lille, INSERM U744, Université Lille Nord de France, Lille, France. 87Department of Epidemiology and Public Health, EA3430, University of Strasbourg, Strasbourg, France. 88Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands. 89Human Genetics Center, University of Texas Health Science Center, Houston, Texas, USA. 90Department of Experimental Medicine, University of Milano-Bicocca, Monza, Italy. 91Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA. 92National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, Massachusetts, USA. 93Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands. 94Clinic for General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany. 95Cardiovascular Research Institute, Washington Hospital Center, Washington, DC, USA. 96Centre for Public Health, The Queen's University of Belfast, Belfast, UK. 97Research Centre for Epidemiology and Preventive Medicine (EPIMED), Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy. 98Department of Cardiology, Toulouse University School of Medicine, Rangueil Hospital, Toulouse, France. 99INSERM UMR S872, Cordeliers Research Centre, Paris, France. 100Division of Research, Kaiser Permanente Northern California,

Oakland, California, USA. 101Icelandic Heart Association, Kopavogur, Iceland. 102Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA. 103Cardiology Division, Department of Internal Medicine, Cardiovascular Genome Center, Yonsei University, Seoul, Korea. 104Department of Clinical Physiology, Tampere University Hospital and University of Tampere, Tampere, Finland. 105UK Clinical Research Collaboration (UKCRC) Centre of Excellence for Public Health (Northern Ireland), Queen's University of Belfast, Belfast, UK. 106Department of Internal Medicine, Cardiovascular Center, Seoul National University Hospital, Seoul, Korea. 107Department of Internal Medicine II—Cardiology, Ulm University Medical Center, Ulm, Germany. 108Science Center, Tampere University Hospital, Tampere, Finland. 109Department of Haematology, University of Cambridge, Cambridge, UK. 110National Health Service (NHS) Blood and Transplant, Cambridge, UK. 111Division of Cardiology, Samsung Medical Center, Seoul, Korea. 112Munich Heart Alliance, Munich, Germany. 113Division of Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. 114Institute for Genomics and Multiscale Biology, Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, New York, USA. 115Center for Human Genetics, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA. 116Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA. 117Division of Cardiology, Department of Medicine, Helsinki University Central Hospital (HUCH), Helsinki, Finland. 118Klinik und Poliklinik für Innere Medizin II, Regensburg, Germany. 119Department of Human Genetics, McGill University, Montréal, Québec, Canada. 120Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts, USA. 121Lebanese American University, Chouran, Beirut, Lebanon. 122Cardiovascular Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. 123Synlab Academy, Mannheim, Germany. 124Cardiology Division, Center for Human Genetic Research, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA. 125Cardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.

CARDIoGRAM members:

Executive Committee: Sekar Kathiresan^{1,2,3}, Muredach P. Reilly⁴, Nilesh J. Samani^{5,6}, Heribert Schunkert^{7,79}

Executive Secretary: Jeanette Erdmann^{7,79}

Steering Committee: Themistocles L. Assimes⁸, Eric Boerwinkle⁹, Jeanette Erdmann^{7,79}, Alistair Hall¹⁰, Christian Hengstenberg¹¹, Sekar Kathiresan^{1,2,3}, Inke R. König¹², Reijo Laaksonen¹³, Ruth McPherson¹⁴, Muredach P. Reilly⁴, Nilesh J. Samani^{5,6}, Heribert Schunkert^{7,79}, John R. Thompson¹⁵, Unnur Thorsteinsdottir^{16,17}, Andreas Ziegler¹²

Statisticians: Inke R. König¹² (chair), John R. Thompson¹⁵ (chair), Devin Absher¹⁸, Li Chen¹⁹, L. Adrienne Cupples^{20,21}, Eran Halperin²², Mingyao Li²³, Kiran Musunuru^{1,2,3}, Michael Preuss^{12,7}, Arne Schillert¹², Gudmar Thorleifsson¹⁶, Benjamin F. Voight^{2,3,24}, George A. Wells²⁵

Writing group: Themistocles L. Assimes⁸, Panos Deloukas²⁶, Jeanette Erdmann^{7,79}, Hilma Holm¹⁶, Sekar Kathiresan^{1,2,3}, Inke R. König¹², Ruth McPherson¹⁴, Muredach P. Reilly⁴, Robert Roberts¹⁴, Nilesh J. Samani^{5,6}, Heribert Schunkert^{7,79}, Alexandre F. R. Stewart¹⁴

ADVANCE: Devin Absher¹⁸, Themistocles L. Assimes⁸, Stephen Fortmann⁸, Alan Go²⁷, Mark Hlatky⁸, Carlos Iribarren²⁷, Joshua Knowles⁸, Richard Myers¹⁸, Thomas Quertermous⁸, Steven Sidney²⁷, Neil Risch²⁸, Hua Tang²⁹

CADomics: Stefan Blankenberg³⁰, Tanja Zeller³⁰, Arne Schillert¹², Philipp Wild³⁰, Andreas Ziegler¹², Renate Schnabel³⁰, Christoph Sinning³⁰, Karl Lackner³¹, Laurence Tiret³², Viviane Nicaud³², Francois Cambien³², Christoph Bickel³⁰, Hans J. Rupprecht³⁰, Claire Perret³², Carole Proust³², Thomas Münzel³⁰

CHARGE: Maja Barbalic³³, Joshua Bis³⁴, Eric Boerwinkle⁹, Ida Yii-Der Chen³⁵, L. Adrienne Cupples^{20,21}, Abbas Dehghan³⁶, Serkalem Demissie-Banjaw^{37,21}, Aaron Folsom³⁸, Nicole Glazer³⁹, Vilmundur Gudnason^{40,41}, Tamara Harris⁴², Susan Heckbert⁴³, Daniel Levy²¹, Thomas Lumley⁴⁴, Kristin Marcianti⁴⁵, Alanna Morrison⁴⁶, Christopher J. O'Donnell⁴⁷, Bruce M. Psaty⁴⁸, Kenneth Rice⁴⁹, Jerome I. Rotter³⁵, David S. Siscovick⁵⁰, Nicholas Smith⁴³, Albert Smith^{40,41}, Kent D. Taylor³⁵, Cornelia van Duijn³⁶, Kelly Volcik⁴⁶, Jaqueline Whitteman³⁶, Vasan Ramachandran⁵¹, Albert Hofman³⁶, Andre Uitterlinden^{52,36}

deCODE: Solveig Gretarsdottir¹⁶, Jeffrey R. Gulcher¹⁶, Hilma Holm¹⁶, Augustine Kong¹⁶, Kari Stefansson^{16,17}, Gudmundur Thorgeirsson^{53,17}, Karl Andersen^{53,17}, Gudmar Thorleifsson¹⁶, Unnur Thorsteinsdottir^{16,17}

GERMIFS I and II: Jeanette Erdmann^{7,79}, Marcus Fischer¹¹, Anika Grosshennig^{12,7}, Christian Hengstenberg¹¹, Inke R. König¹², Wolfgang Lieb⁵⁴, Patrick Linsel-Nitschke⁷, Michael Preuss^{12,7}, Klaus Stark¹¹, Stefan Schreiber⁵⁵, H.-Erich Wichmann^{56,58,59}, Andreas Ziegler¹², Heribert Schunkert⁸⁰

GERMIFS III (KORA): Zouhair Aherrahrou^{7,79}, Petra Bruse^{7,79}, Angela Doering⁵⁶, Jeanette Erdmann^{7,79}, Christian Hengstenberg¹¹, Thomas Illig⁵⁶, Norman Klopp⁵⁶, Inke R. König¹², Patrick Diemert⁷, Christina Loley^{12,7}, Anja Medack^{7,79}, Christina Meisinger⁵⁶, Thomas Meitinger^{57,60}, Janja Nahrstedt^{12,7}, Annette Peters⁵⁶, Michael Preuss^{12,7}, Klaus Stark¹¹, Arnika K. Wagner⁷, H.-Erich Wichmann^{56,58,59}, Christina Willenborg^{7,79}, Andreas Ziegler¹², Heribert Schunkert^{7,79}

LURIC/AtheroRemo: Bernhard O. Böhm⁶¹, Harald Dobnig⁶², Tanja B. Grammer⁶³, Eran Halperin²², Michael M. Hoffmann⁶⁴, Marcus Kleber⁶⁵, Reijo Laaksonen¹³, Winfried März^{63,66,67}, Andreas Meinitzer⁶⁶, Bernhard R. Winkelmann⁶⁸, Stefan Pilz⁶², Wilfried Renner⁶⁶, Hubert Scharnagl⁶⁶, Tatjana Stojakovic⁶⁶, Andreas Tomaschitz⁶², Karl Winkler⁶⁴

MIGen: Benjamin F. Voight^{2,3,24}, Kiran Musunuru^{1,2,3}, Candace Guiducci³, Noel Burt³, Stacey B. Gabriel³, David S. Siscovick⁵⁰, Christopher J. O'Donnell⁴⁷, Roberto Elosua⁶⁹, Leena Peltonen⁴⁹, Veikko Salomaa⁷⁰, Stephen M. Schwartz⁵⁰, Olle Melander²⁶, David Altshuler^{71,3}, Sekar Kathiresan^{1,2,3}

OHGS: Alexandre F. R. Stewart¹⁴, Li Chen¹⁹, Sonny Dandona¹⁴, George A. Wells²⁵, Olga Jarinova¹⁴, Ruth McPherson¹⁴, Robert Roberts¹⁴

PennCATH/MedStar: Muredach P. Reilly⁴, Mingyao Li²³, Liming Qu²³, Robert Wilensky⁴, William Matthai⁴, Hakon H. Hakonarson⁷², Joe Devaney⁷³, Mary Susan Burnett⁷³, Augusto D. Pichard⁷³, Kenneth M. Kent⁷³, Lowell Satler⁷³, Joseph M. Lindsay⁷³, Ron Waksman⁷³, Christopher W. Knouff⁷⁴, Dawn M. Waterworth⁷⁴, Max C. Walker⁷⁴, Vincent Mooser⁷⁴, Stephen E. Epstein⁷³, Daniel J. Rader^{75,4}

WTCCC: Nilesh J. Samani^{5,6}, John R. Thompson¹⁵, Peter S. Braund⁵, Christopher P. Nelson⁵, Benjamin J. Wright⁷⁶, Anthony J. Balmforth⁷⁷, Stephen G. Ball⁷⁸, Alistair S. Hall¹⁰, Wellcome Trust Case Control Consortium

Affiliations CARDIoGRAM

1 Cardiovascular Research Center and Cardiology Division, Massachusetts General Hospital, Boston, MA, USA; 2 Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA, USA; 3 Program in Medical and Population Genetics, Broad Institute of Harvard and Massachusetts Institute of Technology (MIT), Cambridge, MA, USA; 4 The

Cardiovascular Institute, University of Pennsylvania, Philadelphia, PA, USA; 5 Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Leicester, UK; 6 Leicester National Institute for Health Research Biomedical Research Unit in Cardiovascular Disease, Glenfield Hospital, Leicester, LE3 9QP, UK; 7 Institut für integrative und experimentelle Genomik, Universität zu Lübeck, Lübeck, Germany; 8 Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA; 9 University of Texas Health Science Center, Human Genetics Center and Institute of Molecular Medicine, Houston, TX, USA; 10 Division of Cardiovascular and Neuronal Remodelling, Multidisciplinary Cardiovascular Research Centre, Leeds Institute of Genetics, Health and Therapeutics, University of Leeds, UK; 11 Klinik und Poliklinik für Innere Medizin II, Universität Regensburg, Regensburg, Germany; 12 Institut für Medizinische Biometrie und Statistik, Universität zu Lübeck, Lübeck, Germany; 13 Science Center, Tampere University Hospital, Tampere, Finland; 14 The John & Jennifer Ruddy Canadian Cardiovascular Genetics Centre, University of Ottawa Heart Institute, Ottawa, Canada; 15 Department of Health Sciences, University of Leicester, Leicester, UK; 16 deCODE Genetics, 101 Reykjavik, Iceland; 17 University of Iceland, Faculty of Medicine, 101 Reykjavik, Iceland; 18 Hudson Alpha Institute, Huntsville, Alabama, USA; 19 Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, Ontario, Canada, K1Y 4W7; 20 Department of Biostatistics, Boston University School of Public Health, Boston, MA USA; 21 National Heart, Lung and Blood Institute's Framingham Heart Study, Framingham, MA, USA; 22 The Blavatnik School of Computer Science and the Department of Molecular Microbiology and Biotechnology, Tel-Aviv University, Tel-Aviv, Israel, and the International Computer Science Institute, Berkeley, CA, USA; 23 Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, USA; 24 Department of Medicine, Harvard Medical School, Boston, MA, USA; 25 Research Methods, Univ Ottawa Heart Inst; 26 Department of Clinical Sciences, Hypertension and Cardiovascular Diseases, Scania University Hospital, Lund University, Malmö, Sweden; 27 Division of Research, Kaiser Permanente, Oakland, CA, USA; 28 Institute for Human Genetics, University of California, San Francisco, San Francisco, CA, USA; 29 Dept Cardiovascular Medicine, Cleveland Clinic; 30 Medizinische Klinik und Poliklinik, Johannes-Gutenberg Universität Mainz, Universitätsmedizin, Mainz, Germany; 31 Institut für Klinische Chemie und Laboratoriumsmedizin, Johannes-Gutenberg Universität Mainz, Universitätsmedizin, Mainz, Germany; 32 INSERM UMRS 937, Pierre and Marie Curie University (UPMC, Paris 6) and Medical School, Paris, France; 33 University of Texas Health Science Center, Human Genetics Center, Houston, TX, USA; 34 Cardiovascular Health Research Unit and Department of Medicine, University of Washington, Seattle, WA USA; 35 Cedars-Sinai Medical Center, Medical Genetics Institute, Los Angeles, CA, USA; 36 Erasmus Medical Center, Department of Epidemiology, Rotterdam, The Netherlands; 37 Boston University, School of Public Health, Boston, MA, USA; 38 University of Minnesota School of Public Health, Division of Epidemiology and Community Health, School of Public Health (A.R.F.), Minneapolis, MN, USA; 39 University of Washington, Cardiovascular Health Research Unit and Department of Medicine, Seattle, WA, USA; 40 Icelandic Heart Association, Kopavogur Iceland; 41 University of Iceland, Reykjavik, Iceland; 42 Laboratory of Epidemiology, Demography, and Biometry, Intramural Research Program, National Institute on Aging, National Institutes of Health, Bethesda MD, USA; 43 University of Washington, Department of Epidemiology, Seattle, WA, USA; 44 University of Washington, Department of Biostatistics, Seattle, WA, USA; 45 University of Washington, Department of Internal Medicine, Seattle, WA, USA; 46 University of Texas, School of Public Health, Houston, TX, USA; 47 National Heart, Lung and Blood Institute, Framingham Heart Study, Framingham, MA and Cardiology Division, Massachusetts General Hospital, Boston, MA, USA; 48 Center for Health Studies, Group Health, Departments of Medicine, Epidemiology,

and Health Services, Seattle, WA, USA; 49 The Wellcome Trust Sanger Institute, The Wellcome Trust Genome Campus, Hinxton, Cambridge, UK; 50 Cardiovascular Health Research Unit, Departments of Medicine and Epidemiology, University of Washington, Seattle; 51 Boston University Medical Center, Boston, MA, USA; 52 Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands; 53 Department of Medicine, Landspítali University Hospital, 101 Reykjavik, Iceland; 54 Boston University School of Medicine, Framingham Heart Study, Framingham, MA, USA; 55 Institut für Klinische Molekularbiologie, Christian-Albrechts Universität, Kiel, Germany; 56 Institute of Epidemiology, Helmholtz Zentrum München—German Research Center for Environmental Health, Neuherberg, Germany; 57 Institut für Humangenetik, Helmholtz Zentrum München, Deutsches Forschungszentrum für Umwelt und Gesundheit, Neuherberg, Germany; 58 Institute of Medical Information Science, Biometry and Epidemiology, Ludwig-Maximilians-Universität München, Germany; 59 Klinikum Grosshadern, Munich, Germany; 60 Institut für Humangenetik, Technische Universität München, Germany; 61 Division of Endocrinology and Diabetes, Graduate School of Molecular Endocrinology and Diabetes, University of Ulm, Ulm, Germany; 62 Division of Endocrinology, Department of Medicine, Medical University of Graz, Austria; 63 Synlab Center of Laboratory Diagnostics Heidelberg, Heidelberg, Germany; 64 Division of Clinical Chemistry, Department of Medicine, Albert Ludwigs University, Freiburg, Germany; 65 LURIC non profit LLC, Freiburg, Germany; 66 Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University Graz, Austria; 67 Institute of Public Health, Social and Preventive Medicine, Medical Faculty Mannheim, University of Heidelberg, Germany; 68 Cardiology Group Frankfurt-Sachsenhausen, Frankfurt, Germany; 69 Cardiovascular Epidemiology and Genetics Group, Institut Municipal d'Investigació Mèdica, Barcelona; Ciber Epidemiología y Salud Pública (CIBERSP), Spain; 70 Chronic Disease Epidemiology and Prevention Unit, Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland; 71 Department of Molecular Biology and Center for Human Genetic Research, Massachusetts General Hospital, Harvard Medical School, Boston, USA; 72 The Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA; 73 Cardiovascular Research Institute, Medstar Health Research Institute, Washington Hospital Center, Washington, DC 20010, USA; 74 Genetics Division and Drug Discovery, GlaxoSmithKline, King of Prussia, Pennsylvania 19406, USA; 75 The Institute for Translational Medicine and Therapeutics, School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; 76 Department of Cardiovascular Surgery, University of Leicester, Leicester, UK; 77 Division of Cardiovascular and Diabetes Research, Multidisciplinary Cardiovascular Research Centre, Leeds Institute of Genetics, Health and Therapeutics, University of Leeds, Leeds, LS2 9JT, UK; 78 LIGHT Research Institute, Faculty of Medicine and Health, University of Leeds, Leeds, UK; 79 DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck, Lübeck, Germany; 80: Deutsches Herzzentrum München, Technische Universität München München, Germany

Author Contributions

Conceptualization: Ingrid Brænne.

Data curation: Ingrid Brænne, Cristen J. Willer, Markku Laakso, Lars Wallentin, Paul W. Franks, Veikko Salomaa, Abbas Dehghan, Thomas Meitinger, Nilesh J. Samani.

Formal analysis: Ingrid Brænne, Christina Willenborg.

Funding acquisition: Folkert W. Asselbergs, Jeanette Erdmann, Heribert Schunkert.

Investigation: Ingrid Brænne.

Methodology: Ingrid Brænne, Vinicius Tragante.

Resources: Thorsten Kessler.

Software: Lingyao Zeng, Christina Willenborg.

Supervision: Folkert W. Asselbergs, Jeanette Erdmann, Heribert Schunkert.

Validation: Ingrid Brænne.

Visualization: Ingrid Brænne.

Writing – original draft: Ingrid Brænne, Nilesh J. Samani, Folkert W. Asselbergs, Jeanette Erdmann, Heribert Schunkert.

Writing – review & editing: Ingrid Brænne, Jeanette Erdmann, Heribert Schunkert.

References

1. Francis DA. Glatiramer acetate (Copaxone). *Int J Clin Pract*. 2001; 55(6):394–8. PMID: [11501229](#).
2. Arnon R, Aharoni R. Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. *Proc Natl Acad Sci U S A*. 2004; 101 Suppl 2:14593–8. <https://doi.org/10.1073/pnas.0404887101> PMID: [15371592](#); PubMed Central PMCID: PMC521994.
3. Li Q, Milo R, Panitch H, Swoveland P, Bever CT Jr. Glatiramer acetate blocks the activation of THP-1 cells by interferon-gamma. *Eur J Pharmacol*. 1998; 342(2–3):303–10. PMID: [9548401](#).
4. Lalive PH, Neuhaus O, Benkhoucha M, Burger D, Hohlfeld R, Zamvil SS, et al. Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action. *CNS Drugs*. 2011; 25(5):401–14. <https://doi.org/10.2165/11588120-000000000-00000> PMID: [21476611](#); PubMed Central PMCID: PMC3963480.
5. Aharoni R, Kayhan B, Brenner O, Domev H, Labunskay G, Arnon R. Immunomodulatory therapeutic effect of glatiramer acetate on several murine models of inflammatory bowel disease. *J Pharmacol Exp Ther*. 2006; 318(1):68–78. <https://doi.org/10.1124/jpet.106.103192> PMID: [16624971](#).
6. Aharoni R, Kayhan B, Eilam R, Sela M, Arnon R. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. *Proc Natl Acad Sci U S A*. 2003; 100(24):14157–62. <https://doi.org/10.1073/pnas.2336171100> PMID: [14614135](#); PubMed Central PMCID: PMC283562.
7. Tsareva EY, Kulakova OG, Boyko AN, Shchur SG, Lvovs D, Favorov AV, et al. Allelic combinations of immune-response genes associated with glatiramer acetate treatment response in Russian multiple sclerosis patients. *Pharmacogenomics*. 2012; 13(1):43–53. <https://doi.org/10.2217/pgs.11.136> PMID: [22111603](#).
8. Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. *Nat Genet*. 2003; 34(2):154–6. <https://doi.org/10.1038/ng1161> PMID: [12730697](#).
9. Tg and Hdl Working Group of the Exome Sequencing Project National Heart Lung Blood Institute, Crosby J, Peloso GM, Auer PL, Crosslin DR, Stitzel NO, et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. *N Engl J Med*. 2014; 371(1):22–31. <https://doi.org/10.1056/NEJMoa1307095> PMID: [24941081](#); PubMed Central PMCID: PMC4180269.
10. Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. *N Engl J Med*. 2016; 374(19):1898. <https://doi.org/10.1056/NEJMxx160012> PMID: [27168448](#).
11. Schunkert H. Brotherhood of genetics and preventive medication. *Eur Heart J*. 2015; 36(25):1566–8. <https://doi.org/10.1093/eurheartj/ehv153> PMID: [25953708](#).
12. Johnson JA, Cavallari LH. Pharmacogenetics and cardiovascular disease—implications for personalized medicine. *Pharmacol Rev*. 2013; 65(3):987–1009. <https://doi.org/10.1124/pr.112.007252> PMID: [23686351](#); PubMed Central PMCID: PMC3698938.
13. Brænne I, Willenborg C, Reiz B, Zeng L, Tragante do Ó V, Meitinger T, et al. Pleiotropic molecular targets of coxibs reveals novel genomic loci conferring coronary artery disease risk. *Atherosclerosis*. 2016; e252–e3. <https://doi.org/10.1016/j.atherosclerosis.2016.07.066>
14. Consortium CAD. A comprehensive 1000 Genomes-based genome-wide association meta-analysis of coronary artery disease. *Nat Genet*. 2015. <https://doi.org/10.1038/ng.3396> PMID: [26343387](#).

15. Griffith M, Griffith OL, Coffman AC, Weible JV, McMichael JF, Spies NC, et al. DGIdb: mining the drug-gable genome. *Nat Methods*. 2013; 10(12):1209–10. <https://doi.org/10.1038/nmeth.2689> PMID: [24122041](#); PubMed Central PMCID: PMC3851581.
16. Schunkert H, Konig IR, Kathiresan S, Reilly MP, Assimes TL, Holm H, et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. *Nat Genet*. 2011; 43(4):333–8. <https://doi.org/10.1038/ng.784> PMID: [21378990](#); PubMed Central PMCID: PMC3119261.
17. CARDIoGRAMplusC4D-Consortium, Deloukas P, Kanoni S, Willenborg C, Farrall M, Assimes TL, et al. Large-scale association analysis identifies new risk loci for coronary artery disease. *Nat Genet*. 2013; 45(1):25–33. <https://doi.org/10.1038/ng.2480> PMID: [23202125](#); PubMed Central PMCID: PMC3679547.
18. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986; 7(3):177–88. PMID: [3802833](#).
19. Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. *Nucleic Acids Res*. 2012; 40(Database issue): D930–4. <https://doi.org/10.1093/nar/gkr917> PMID: [22064851](#); PubMed Central PMCID: PMC3245002.
20. Yang J, Ferreira T, Morris AP, Medland SE, Genetic Investigation of ATC, Replication DIG, et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. *Nat Genet*. 2012; 44(4):369–75, S1–3. <https://doi.org/10.1038/ng.2213> PMID: [22426310](#); PubMed Central PMCID: PMC3593158.
21. Westra HJ, Peters MJ, Esko T, Yaghootkar H, Schurmann C, Kettunen J, et al. Systematic identification of trans eQTLs as putative drivers of known disease associations. *Nat Genet*. 2013; 45(10):1238–43. <https://doi.org/10.1038/ng.2756> PMID: [24013639](#); PubMed Central PMCID: PMC3591562.
22. Consortium GT. Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. *Science*. 2015; 348(6235):648–60. <https://doi.org/10.1126/science.1262110> PMID: [25954001](#).
23. Leslie R, O'Donnell CJ, Johnson AD. GRASP: analysis of genotype-phenotype results from 1390 genome-wide association studies and corresponding open access database. *Bioinformatics*. 2014; 30(12):i185–94. <https://doi.org/10.1093/bioinformatics/btu273> PMID: [24931982](#); PubMed Central PMCID: PMC4072913.
24. Boyle AP, Hong EL, Hariharan M, Cheng Y, Schaub MA, Kasowski M, et al. Annotation of functional variation in personal genomes using RegulomeDB. *Genome Res*. 2012; 22(9):1790–7. <https://doi.org/10.1101/gr.137323.112> PMID: [22955989](#); PubMed Central PMCID: PMC3431494.
25. Weber MS, Hohlfeld R, Zamvil SS. Mechanism of action of glatiramer acetate in treatment of multiple sclerosis. *Neurotherapeutics*. 2007; 4(4):647–53. <https://doi.org/10.1016/j.nurt.2007.08.002> PMID: [17920545](#).
26. Grainger DJ. TGF-beta and atherosclerosis in man. *Cardiovasc Res*. 2007; 74(2):213–22. <https://doi.org/10.1016/j.cardiores.2007.02.022> PMID: [17382916](#).
27. Mallat Z, Tedgui A. The role of transforming growth factor beta in atherosclerosis: novel insights and future perspectives. *Curr Opin Lipidol*. 2002; 13(5):523–9. PMID: [12352016](#).
28. Grainger DJ. Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis. *Arterioscler Thromb Vasc Biol*. 2004; 24(3):399–404. <https://doi.org/10.1161/01.ATV.0000114567.76772.33> PMID: [14699019](#).
29. Bobik A. Transforming growth factor-betas and vascular disorders. *Arterioscler Thromb Vasc Biol*. 2006; 26(8):1712–20. <https://doi.org/10.1161/01.ATV.0000225287.20034.2c> PMID: [16675726](#).
30. Wang XL, Liu SX, Wilcken DE. Circulating transforming growth factor beta 1 and coronary artery disease. *Cardiovasc Res*. 1997; 34(2):404–10. PMID: [9205555](#).
31. Ruiz-Ortega M, Rodriguez-Vita J, Sanchez-Lopez E, Carvajal G, Egido J. TGF-beta signaling in vascular fibrosis. *Cardiovasc Res*. 2007; 74(2):196–206. <https://doi.org/10.1016/j.cardiores.2007.02.008> PMID: [17376414](#).
32. Bujak M, Frangogiannis NG. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. *Cardiovasc Res*. 2007; 74(2):184–95. <https://doi.org/10.1016/j.cardiores.2006.10.002> PMID: [17109837](#); PubMed Central PMCID: PMC1924687.
33. Gordon KJ, Blobel GC. Role of transforming growth factor-beta superfamily signaling pathways in human disease. *Biochim Biophys Acta*. 2008; 1782(4):197–228. <https://doi.org/10.1016/j.bbadis.2008.01.006> PMID: [18313409](#).
34. Zeng L, Dang TA, Schunkert H. Genetics links between transforming growth factor beta pathway and coronary disease. *Atherosclerosis*. 2016; 253:237–46. <https://doi.org/10.1016/j.atherosclerosis.2016.08.029> PMID: [27596813](#).

35. Braenne I, Civelek M, Vilne B, Di Narzo A, Johnson AD, Zhao Y, et al. Prediction of Causal Candidate Genes in Coronary Artery Disease Loci. *Arterioscler Thromb Vasc Biol*. 2015; 35(10):2207–17. <https://doi.org/10.1161/ATVBAHA.115.306108> PMID: 26293461; PubMed Central PMCID: PMC4583353.
36. Lebrin F, Deckers M, Bertolino P, Ten Dijke P. TGF-beta receptor function in the endothelium. *Cardio-vasc Res*. 2005; 65(3):599–608. <https://doi.org/10.1016/j.cardiores.2004.10.036> PMID: 15664386.
37. Yamamoto K, Morishita R, Tomita N, Shimozato T, Nakagami H, Kikuchi A, et al. Ribozyme oligonucleotides against transforming growth factor-beta inhibited neointimal formation after vascular injury in rat model: potential application of ribozyme strategy to treat cardiovascular disease. *Circulation*. 2000; 102(11):1308–14. PMID: 10982548.
38. Ward MR, Agrotis A, Kanellakis P, Hall J, Jennings G, Bobik A. Tranilast prevents activation of transforming growth factor-beta system, leukocyte accumulation, and neointimal growth in porcine coronary arteries after stenting. *Arterioscler Thromb Vasc Biol*. 2002; 22(6):940–8. PMID: 12067902.
39. Schini-Kerth VB, Bassus S, Fisslthaler B, Kirchmaier CM, Busse R. Aggregating human platelets stimulate the expression of thrombin receptors in cultured vascular smooth muscle cells via the release of transforming growth factor-beta1 and platelet-derived growth factorAB. *Circulation*. 1997; 96(11):3888–96. PMID: 9403612.
40. Lev PR, Salim JP, Marta RF, Osorio MJ, Goette NP, Molinas FC. Platelets possess functional TGF-beta receptors and Smad2 protein. *Platelets*. 2007; 18(1):35–42. <https://doi.org/10.1080/09537100600800743> PMID: 17365852.
41. Mo JW, Zhang DF, Ji GL, Liu XZ, Fan B. TGF-beta1 and Serpine 1 expression changes in traumatic deep vein thrombosis. *Genet Mol Res*. 2015; 14(4):13835–42. <https://doi.org/10.4238/2015.October.29.3> PMID: 26535698.
42. Lijnen PJ, Petrov VV, Fagard RH. Association between transforming growth factor-beta and hypertension. *Am J Hypertens*. 2003; 16(7):604–11. PMID: 12850397.
43. Kurihara H, Yoshizumi M, Sugiyama T, Takaku F, Yanagisawa M, Masaki T, et al. Transforming growth factor-beta stimulates the expression of endothelin mRNA by vascular endothelial cells. *Biochem Biophys Res Commun*. 1989; 159(3):1435–40. PMID: 2649101.
44. Stoynev N, Dimova I, Rukova B, Hadjidekova S, Nikolova D, Toncheva D, et al. Gene expression in peripheral blood of patients with hypertension and patients with type 2 diabetes. *J Cardiovasc Med (Hagerstown)*. 2014; 15(9):702–9. <https://doi.org/10.2459/JCM.0b013e32835dbcc8> PMID: 23337395.